PL3897578T3 - Schematy dawkowania ly3154207 w leczeniu zaburzeń dopaminergicznych ośrodkowego układu nerwowego - Google Patents
Schematy dawkowania ly3154207 w leczeniu zaburzeń dopaminergicznych ośrodkowego układu nerwowegoInfo
- Publication number
- PL3897578T3 PL3897578T3 PL19836884.7T PL19836884T PL3897578T3 PL 3897578 T3 PL3897578 T3 PL 3897578T3 PL 19836884 T PL19836884 T PL 19836884T PL 3897578 T3 PL3897578 T3 PL 3897578T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- cns disorders
- dose regimens
- dopaminergic
- dopaminergic cns
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781251P | 2018-12-18 | 2018-12-18 | |
| US201962904048P | 2019-09-23 | 2019-09-23 | |
| PCT/US2019/066465 WO2020131671A1 (en) | 2018-12-18 | 2019-12-16 | Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3897578T3 true PL3897578T3 (pl) | 2025-03-10 |
Family
ID=69167914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19836884.7T PL3897578T3 (pl) | 2018-12-18 | 2019-12-16 | Schematy dawkowania ly3154207 w leczeniu zaburzeń dopaminergicznych ośrodkowego układu nerwowego |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20220062265A1 (pl) |
| EP (2) | EP3897578B1 (pl) |
| JP (4) | JP2022514659A (pl) |
| KR (2) | KR20210111783A (pl) |
| CN (1) | CN113347961A (pl) |
| AU (1) | AU2019402087B2 (pl) |
| BR (1) | BR112021012102A2 (pl) |
| CA (1) | CA3124416C (pl) |
| DK (1) | DK3897578T3 (pl) |
| ES (1) | ES3004543T3 (pl) |
| FI (1) | FI3897578T3 (pl) |
| HR (1) | HRP20241778T1 (pl) |
| HU (1) | HUE069782T2 (pl) |
| IL (1) | IL284175A (pl) |
| LT (1) | LT3897578T (pl) |
| MA (2) | MA71651A (pl) |
| MD (1) | MD3897578T2 (pl) |
| MX (1) | MX2021007442A (pl) |
| MY (1) | MY209406A (pl) |
| PL (1) | PL3897578T3 (pl) |
| PT (1) | PT3897578T (pl) |
| RS (1) | RS66337B1 (pl) |
| SG (1) | SG11202106595VA (pl) |
| SI (1) | SI3897578T1 (pl) |
| TW (2) | TWI831896B (pl) |
| UA (1) | UA126882C2 (pl) |
| WO (1) | WO2020131671A1 (pl) |
| ZA (1) | ZA202104466B (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023010540A (es) * | 2021-03-08 | 2023-11-24 | Lilly Co Eli | Uso de mevidaleno y otros moduladores alostéricos positivos d1 en el tratamiento de alucinaciones y psicosis relacionadas con la demencia. |
| AU2022234226B2 (en) * | 2021-03-09 | 2025-08-14 | Eli Lilly And Company | Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3316B1 (ar) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| ES2973289T3 (es) * | 2014-09-04 | 2024-06-19 | Lobsor Pharmaceuticals Ab | Composiciones farmacéuticas en gel que comprenden levodopa, carbidopa y entacapona |
| AR106332A1 (es) * | 2015-10-23 | 2018-01-03 | Lilly Co Eli | Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona |
-
2019
- 2019-12-16 TW TW108146071A patent/TWI831896B/zh active
- 2019-12-16 LT LTEPPCT/US2019/066465T patent/LT3897578T/lt unknown
- 2019-12-16 MA MA71651A patent/MA71651A/fr unknown
- 2019-12-16 CA CA3124416A patent/CA3124416C/en active Active
- 2019-12-16 HR HRP20241778TT patent/HRP20241778T1/hr unknown
- 2019-12-16 MA MA54530A patent/MA54530B1/fr unknown
- 2019-12-16 MD MDE20211050T patent/MD3897578T2/ro unknown
- 2019-12-16 ES ES19836884T patent/ES3004543T3/es active Active
- 2019-12-16 WO PCT/US2019/066465 patent/WO2020131671A1/en not_active Ceased
- 2019-12-16 EP EP19836884.7A patent/EP3897578B1/en active Active
- 2019-12-16 BR BR112021012102-1A patent/BR112021012102A2/pt unknown
- 2019-12-16 TW TW112133925A patent/TWI892226B/zh active
- 2019-12-16 EP EP24180893.0A patent/EP4417258A3/en active Pending
- 2019-12-16 MY MYPI2021003450A patent/MY209406A/en unknown
- 2019-12-16 PT PT198368847T patent/PT3897578T/pt unknown
- 2019-12-16 KR KR1020217022499A patent/KR20210111783A/ko not_active Ceased
- 2019-12-16 HU HUE19836884A patent/HUE069782T2/hu unknown
- 2019-12-16 DK DK19836884.7T patent/DK3897578T3/da active
- 2019-12-16 MX MX2021007442A patent/MX2021007442A/es unknown
- 2019-12-16 AU AU2019402087A patent/AU2019402087B2/en active Active
- 2019-12-16 PL PL19836884.7T patent/PL3897578T3/pl unknown
- 2019-12-16 SG SG11202106595VA patent/SG11202106595VA/en unknown
- 2019-12-16 UA UAA202103923A patent/UA126882C2/uk unknown
- 2019-12-16 JP JP2021535892A patent/JP2022514659A/ja not_active Withdrawn
- 2019-12-16 FI FIEP19836884.7T patent/FI3897578T3/fi active
- 2019-12-16 KR KR1020257015518A patent/KR20250069706A/ko active Pending
- 2019-12-16 US US17/416,320 patent/US20220062265A1/en active Pending
- 2019-12-16 RS RS20241415A patent/RS66337B1/sr unknown
- 2019-12-16 SI SI201930869T patent/SI3897578T1/sl unknown
- 2019-12-16 CN CN201980089891.3A patent/CN113347961A/zh active Pending
-
2021
- 2021-06-18 IL IL284175A patent/IL284175A/en unknown
- 2021-06-28 ZA ZA2021/04466A patent/ZA202104466B/en unknown
-
2023
- 2023-01-24 JP JP2023008488A patent/JP2023055770A/ja active Pending
-
2025
- 2025-08-06 JP JP2025131198A patent/JP2025163202A/ja active Pending
- 2025-08-06 JP JP2025131199A patent/JP2025163203A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276398A (en) | Combined treatment for mastocytosis | |
| IL273031A (en) | Combined treatment of lasmiditan and a CGRP antagonist for use in the treatment of migraine | |
| IL279636A (en) | Use of sCG agonists to treat mitochondrial disorders | |
| IL278889A (en) | Dosing regimen for the treatment of PI3K-related disorders | |
| SI3452465T1 (sl) | Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| IL284175A (en) | Dosing regimens in the use of LY3154207 in the treatment of diseases of the dopaminergic central nervous system | |
| IL264139A (en) | Dosing regimens of LINGO-1 antagonists and uses for the treatment of demyelinating disorders | |
| IL281997A (en) | Combined treatment for the treatment of uveal melanoma | |
| IL283031A (en) | And will grow to treat the symptoms of overactivity in the gland | |
| IL277805A (en) | Use of gaboksadol in the treatment of substance use disorders | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| IL284032A (en) | 3 beta-(benzyloxy)-17 alpha-methyl-paragan-5-en-20-one for use in the treatment of cognitive disorders | |
| IL276697A (en) | 3 Beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders | |
| PL3148990T3 (pl) | Związki tiazolidynonu i ich zastosowanie w leczeniu zaburzeń psychiatrycznych neurologicznych i stanów zapalnych, w szczególności stanów zapalnych układu nerwowego | |
| ZA201806894B (en) | (+)-azasetron for use in the treatment of ear disorders | |
| PT3442537T (pt) | (+)-azasetrom para utilização no tratamento de doenças do ouvido | |
| IL253037A0 (en) | (alpha)-ethynyl-3(beta)-hydroxy-5(alpha)-paragnane-20-oxime for use in the treatment of central nervous system disorders | |
| PT3148990T (pt) | Compostos de tiazolidinona e seu uso no tratamento de condições psiquiátricas ou distúrbios neurológicos e inflamação, particularmente neuroinflamação |